Oppenheimer Maintains Outperform on Evaxion Biotech, Lowers Price Target to $11

Benzinga Real-time News ·  Nov 17, 2022 08:36

Oppenheimer analyst Jeff Jones maintains Evaxion Biotech (NASDAQ:EVAX) with a Outperform and lowers the price target from $16 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment